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Abstract
Recently, the tissue origin of MDA-MB-435 cell line has been the subject of considerable debate. In this study,
we set out to determine whether MDA-MB-435-DTP cells shown to express melanoma-specific genes were identi-
cal to various other MDA-MB-435 cell stocks worldwide. CGH-microarray, genetic polymorphism genotyping,
microsatellite fingerprint analysis and/or chromosomal number confirmed that the MDA-MB-435 cells main-
tained at the Lombardi Comprehensive Cancer Center (MDA-MB-435-LCC) are almost identical to the MDA-
MB-435-DTP cells, and showed a very similar profile to those obtained from the same original source (MD
Anderson Cancer Center) but maintained independently (MDA-MB-435-PMCC). Gene expression profile analy-
sis confirmed common expression of genes among different MDA-MB-435-LCC cell stocks, and identified some
unique gene products in MDA-MB-435-PMCC cells. RT-PCR analysis confirmed the expression of the mela-
noma marker tyrosinase across multiple MDA-MB-435 cell stocks. Collectively, our results show that the MDA-
MB-435 cells used widely have identical origins to those that exhibit a melanoma-like gene expression signature,
but exhibit a small degree of genotypic and phenotypic drift.
Abbreviations: CGH – comparative genomic hybridisation; EGF – epidermal growth factor
Introduction
The MDA-MB-435 cell line was established from pleu-
ral effusion from a 31-year-old breast cancer patient
who died in 1976 within one year of diagnosis [1]. The
pathology showed residual tumour throughout the
breast, draining lymphatics and axillary lymph nodes.
Tumorigenicity and metastatic potential of the cell line
in athymic nude mice was originally shown in 1990 [2,
3], and they have since been employed extensively as
one of the most metastatic human breast cancer cell
lines available (reviewed in [4, 5]).
Controversy over the origin and/or provenance of
these cells was sparked by the observation that the
MDA-MB-435 cells used by the National Cancer Insti-
tute’s Developmental Therapeutics Program 60
(NCI60) cell line screen (designated MDA-MB-435-
DTP) exhibited a melanoma-like gene expression
profile when subjected to gene array analysis [6]. Mela-
noma-like characteristics have since also been reported
by others in terms of protease activity profiling [7], the
expression of genes involved in melanin biosynthesis
[8, 9], lack of expression of genes characteristic of
breast cancer [9], and patterns of secreted proteins
[10]. However, since there has been no direct link
established between the MDA-MB-435 cells used in
these studies and those used commonly in other labo-
ratories, the possibility existed that the cells used in
the NCI60 cell screen [6] were cross-contaminated with
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a melanoma cell line and/or that they were of a differ-
ent origin from the MDA-MB-435 cells used by most
breast cancer researchers, including ourselves.
To test this possibility, we compared MDA-MB-
435-LCC cells routinely used in our laboratories with
those used in the NCI60 cell screens (MDA-MB-435-
DTP) using microarray-comparative genomic hybridi-
sation (CGH), genetic polymorphism genotyping and
short tandem repeat fingerprint analysis, and used RT-
PCR to confirm the expression of the melanocyte-
specific tyrosinase gene among cell lines. We further
compared the MDA-MB-435-LCC cells with
MDA-MB-435 cells obtained separately from the MD
Anderson laboratory source (MDA-MB-435-PMCC)
using CGH, microsatellite analysis, chromosome num-
ber and gene expression profiling.
Our results collectively showed that the MDA-MB-
435 cell lines from various sources are of the same ori-
gin, with slight changes being introduced as they
evolve over time, consistent with phenotypic drift.
They are genetically linked to MDA-MB-435-DTP
cells, and thus all exhibit characteristics of a mela-
noma-like signature. We conclude that, based on cur-
rent information, MDA-MB-435 cells are not a
definitive model for breast cancer, although the possi-
bility remains that they represent breast cancer cells
which have undergone a transdifferentiation to mela-
noma-like cells or acquired melanoma features through
lineage infidelity. They remain an important model for
the study of various aspects of human cancer cell
metastasis.
Materials and methods
Cell lines
MDA-MB-435 cells originally obtained from Dr Janet
Price, MD Anderson Cancer Center in the late 1980s,
and maintained by the Lombardi Cancer Center Tissue
Shared Resource have been designated MDA-MB-435-
LCC. MDA-MB-435 cells obtained from Dr Janet
Price in 1997 and maintained at the Peter MacCallum
Cancer Center, Melbourne, Australia have been desig-
nated MDA-MB-435-PMCC. MDA-MB-435/LCC6
cells, adapted to growth as ascites [11], were obtained
from the Lombardi Cancer Center Tissue Shared
Resource. The MDA-MB-435S cells were obtained
from the ATCC (Manassas, Virginia) and the MDA-
MB-435 cells used in the NCI60 cell screening program
(designated here as MDA-MB-435-DTP) were
obtained from Dr Dominic A. Scudiero of the
National Institute of Health FCRDC. MDA-MB-468,
MDA-MB-453, T47D, and SK-Br-3 cell lines were
originally obtained from the ATCC. MCF-7ADR/NCI/
ADR-RES cells [12], were originally obtained from
Dr Ken Cowan, NCI. The MDA-MB-435-LCC15 cells
were previously designated LCC15-MB, but were
recently shown to be MDA-MB-435-LCC (Thompson
et al. [30]. PMC42-LA cells [13] were obtained from
Dr Leigh Ackland, Deakin University, Melbourne,
Australia.
Comparative genomic hybridisation (CGH) analysis
CGH was carried out according to methods described
in detail elsewhere [14] using the same method as
Thompson et al. [30]. The cell line and normal DNA
samples were labelled during a DOP-PCR reaction,
with digoxigenin and biotin and detected indirectly
with anti-digoxigenin–fluorescein and avidin-rhoda-
mine [31].
Microsatellite analysis
Cell line genomic DNA was analysed for nine micro-
satellite markers D7S518 (7q31), D7S666 (7q22.1),
D8S300 (8q23.1), D8S326 (8q23.2), CYP19 (15q21),
AIB1 (20q12), D22S284 (22q13.1), D22S307 (22q13.1)
and D22S275 (22q12.1). The sequences of the primers
are available at http://www.gdb.org/. The forward
primers were labelled with a fluorescent dye (FAM or
HEX, GeneWorks Pty Ltd, Adelaide, Australia). After
PCR amplification, the products were denatured in
90% formamide and the alleles separated by electro-
phoresis through 6% denaturing polyacrylamide gels.
The alleles were detected using a scanning laser fluo-
rescence imager (Bio-Rad Molecular Imager FX). Six
microsatellite markers on chromosome 8p were also
tested (D8s550, D8s532, D8s1820, D8s136, D8s1706,
D8s255) as described in Venter et al. (in preparation).
Ploidy analysis
Metaphase chromosome spreads were prepared from
the cell lines using standard methods and the slides
were stained with DAPI in phenyldiamine antifade
solution. Metaphase chromosomes were viewed under
a Zeiss fluorescence microscope and captured as
described for CGH. The number of chromosomes in
each of at least 25 spreads were counted using the
Quips CGH karyotype program. The modal number
of chromosomes and range was determined for each
cell line.
Fluorescent in situ hybridisation (FISH)
FISH on metaphase chromosome spreads of the cell
lines was as described in Venter et al. (in preparation).
Ten probes on chromosome 8 were analysed; six
probes were on chromosome 8p, three on 8q and one
was at the centromere.
Expression array profiling
Cell lines were cultured under standard conditions
using RPMI supplemented with 10% foetal calf
serum. RNA collections were made (RNeasy kit,
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Qiagen, Valencia, California) at mid-log growth phase
and at 80% plate coverage. RNA quality was
gauged using spectrophotometric readings and the Ag-
ilent Bioanalyzer (Agilent Technologies, Palo Alto,
California). Research Genetics GF225 filter arrays
(Research Genetics, Huntsville, Alabama) which con-
tain 5000 spotted ‘breast-enriched’ cDNAs were
used. A standard protocol recommended by the man-
ufacturer was followed for isotope labelling and inter-
rogation using 4 lg (total) RNA. Following image
analysis and data extraction (Pathways 3.0, Research
Genetics), we applied selective filters to reduce the ini-
tial 5000 gene set to a 3800-gene subset for the pres-
ent analysis. This included removal of genes whose
expression value was lower than a set threshold level
and/or with low variance across all cell line samples
analysed. An unsupervised hierarchical clustering
algorithm was applied separately to the cell lines and
genes, using the Pearson correlation coefficient as the
measure of similarity and average linkage clustering
[15]. The results are presented as dendrogram trees in
which very similar elements are connected by short
branches, and longer branches join elements with
diminishing degrees of similarity. The gene cluster tree
(vertical matrix axis) and gene IDs have been
removed from the figure to enhance clarity, however
gene IDs from each of the three more discriminatory
clusters are shown in Table 6.
CGH-microarrays: AmpliOnc I array analysis
High molecular weight genomic DNA from the MDA-
MB-435-DTP cell line was kindly provided by Domi-
nic A. Scudiero. DNA from MDA-MB-435-LCC cells
was extracted using the Qiagen DNeasy Tissue kit
(Qiagen Inc., Valencia, California). Genomic DNA
was labelled with Alexa-488 (green) dUTP and hybri-
dised to the AmpliOnc I CGH-microarray in the
presence of Alexa-594 (red) dUTP-labelled normal
male reference DNA, according to the manufacturer’s
protocol (Vysis Inc., Downers Grove, Illinois), and as
described in detail elsewhere [16]. Analysis of green/red
intensity ratios allowed a modal DNA copy number to
be calculated for each test DNA.
Genotyping for polymorphic drug metabolizing enzymes
Cell lines were assayed for genetic polymorphisms in
the cytochrome P450 (CYP) 2C8, 2C9, 2C19 and 2D6
enzymes, and the (C3435T) polymorphism in the mul-
tidrug-resistance (MDR)/P-glycoprotein transporter
using conventional polymerase chain reaction – restric-
tion fragment length polymorphism (PCR–RFLP)
assays as described in detail elsewhere [17].
Genetic finger printing
High molecular weight genomic DNA from the MDA-
MB-435-DTP and the MDA-MB-435-LCC cells was
sent to Orchid Cellmark (Nashville, Tennessee) for
short tandem repeat (STR) PCR analysis.
RT-PCR analysis of tyrosinase gene expression
Tyrosinase gene expression was assayed by RT-PCR
assay using standard methods. Briefly, total cellular
RNA was prepared from the cells using RNAzol (Iso-
Tex Diagnostics, Friendswood, Texas) according to
the manufacturer’s instructions. RNA was quantitated
by absorbance at 260 nm and integrity was verified by
gel electrophoresis. Samples (1 lg) of total RNA were
subjected to reverse transcription into cDNA followed
by PCR amplification of tyrosinase sequences using
commercial RT and PCR reagents according to the
manufacturer’s instructions (Pharmacia, New Jersey).
Tyrosinase specific primers (50-TGT CAA TGG ATG
CAC TGC TTG -30 and 50–GGT TTC CAG GAT
TAC GCC GTA–30) were synthesised by Integrated
DNA Technologies (Coralville, Iowa), and the reaction
resulted in the amplification of a 365 bp fragment
from cDNA, but not from genomic DNA being sepa-
rated by more than 12.7 kb in the genomic sequence.
Results
We obtained DNA from the MDA-MB-435-DTP cells
arrayed by Ross et al. (2000) [6] to compare it with
DNA from the same cell line which was obtained from
the same original source (MDA-MB-435-LCC) and
used in our institutions. AmpliOnc I CGH-micro-
array analysis indicated that the gene copy levels are
almost identical between the two cell lines (Table 1). It
is notable that the cells did not exhibit any of the gene
amplifications typically found in breast cancers, such
as c-Myc, erbB2, EGFR or AIB1. In fact, neither the
MDA-MB-435-LCC or MDA-MB-435-DTP cells
showed obvious amplification of any of the 59
oncogenes measured by this CGH-microarray. We
genotyped these cells, along with the MDA-MB-435/
LCC-6 cell line variant, for a number of genetic poly-
morphisms in drug metabolising enzymes (Table 2).
All three cell lines were homozygous for the wild-type
alleles of CYP2C8, CYP2C9, CYP2C19 and
CYP2D6*6, and, interestingly, all were homozygous
for the rare CYP2D6*4 allele (Figure 1) as well as for
the genetic polymorphism in the MDR1 gene.
Table 1. Gene copy numbers determined by CGH-microarray.
Cyto location Gene MDA-
MB-435-
DTP
Std dev MDA-
MB-435-
LCC
Std dev
1p36.2-p36.1 FGR 0.94 0.05 1.11 0.11
1p34.3 MYCL1 0.90 0.06 1.13 0.17
1p13.2 NRAS 0.92 0.11 1.04 0.14
1q25-q31 LAMC2 0.89 0.05 1.18 0.05
Common origins of MDA-MB-435 cells 545
The genotype data prompted us to undertake
genetic fingerprint analysis of the MDA-MB-435-LCC
and MDA-MB-435-DTP cell lines (Table 3). MDA-
MB-435-LCC cells were consistent with MDA-MB-
435-DTP at 13 of the 14 loci, however at D7S820 the
MDA-MB-435-LCC cells were homozygous [8] whilst
the MDA-MB-435-DTP cells were heterozygous [8, 10].
In addition, MDA-MB-435-DTP cells have four loci
with unbalanced alleles (peak height ratio
£ 60%) and the MDA-MB-435-LCC cells are unbal-
anced at two loci. In total, these results indicate that
the two cell lines originated from the same parental cell
line and that a small degree of clonal drift has
occurred.
CGH analysis of such drift between the MDA-MB-
435-LCC and MDA-MB-435-PMCC cell lines showed
similarities with gain of 3p14-qter, 6p11-cen, and 20q,
and losses at Xp21-cen and Xq22-q24 (data not
shown). Gains at 8q23-qter and 11cen-q13 and loss at
18p were unique to the MDA-MB-435-LCC cell line.
The MDA-MB-435-PMCC cell line also had a unique
change with gain at 7q22-qter.
Higher resolution fingerprinting of these cells lines
by microsatellite analysis at nine markers on five chro-
mosome arms confirmed the high degree of similarity
between MDA-MB-435-LCC cells and MDA-MB-435-
PMCC cells. The only difference was the loss of one of
the alleles for two markers at 8q23 (D8S300 and
D8S326 in MDA-MB-435-LCC compared to MDA-
MB-435-PMCC (Figure 2). Higher density microsatel-
lite analysis of chromosome 8p confirmed these
differences seen on chromosome 8 between MDA-MB-
435-LCC and MDA-MB-435-PMCC. All markers on
8p showed loss of one allele in the MDA-MB-435-LCC
cell line (Table 4). On high density fluorescent in situ
hybridisation (FISH) analysis, the MDA-MB-435-
PMCC cells appeared to have three complete copies of
chromosome 8. There appeared to be 2 normal chro-
mosome 8s. The other chromosome 8 material was dis-
tributed over two chromosomes due to a translocation
with a breakpoint between 8q22.1 and 8q24.1 (Fig-
ure 3). For the MDA-MB-435-LCC cell line, one of
these four chromosomes had been lost leaving the two
normal chromosome 8s and a chromosome with two
copies of the 8q24.1 probe. This loss of one of the
chromosomes in the MDA-MB-435-LCC cell line
resulted in the LOH detected by microsatellite analysis.
MDA-MB-435-PMCC cells showed a modal num-
ber of 57 chromosomes (16 of 26 spreads), with a
range of 44–59. The loss of one copy of chromosome
8 from the MDA-MB-435-LCC cell line was consistent
with our observation of a decrease in the modal num-
ber to 52 chromosomes. The MDA-MB-435-LCC cell
line has 52 chromosomes (9 of 26 spreads with 52; 7
of 26 with 51), with a range of 46–52 (Thompson et al.
[30]).
The FISH results shown for the MDA-MB-435-
PMCC cell line resemble the SKY results obtained by
Davidson et al. [18] in Europe. Both methods show four
Table 1. Continued.
Cyto location Gene MDA-
MB-
435-
DTP
Std dev MDA-
MB-
435-
LCC
Std dev
2p24.1 MYCN 0.93 0.09 1.12 0.20
2p13-p12 REL 1.01 0.01 1.01 0.10
3p25 RAF1 0.88 0.05 0.77 0.03
3q26.3 TERC 1.18 0.02 1.56 0.18
3q26.3 PIK3CA 1.31 0.17 1.55 0.13
4q12 PDGFRA 0.84 0.04 1.11 0.10
6q22 MYB 0.89 0.03 0.97 0.06
6q25.1 ESR 0.90 0.13 0.96 0.03
7p12.3-p12.1 EGFR 0.83 0.01 1.22 0.09
7q21.1 PGY1 1.05 0.07 1.08 0.10
7q31 MET 1.36 0.18 1.03 0.02
8p22 CTSB 1.02 0.02 N.D N.D
8p11.2-p11.1 FGFR1 1.03 0.03 1.03 0.02
8q11 MOS 1.00 0.02 0.77 0.01
8q24.12-q24.13 MYC 1.09 0.11 1.08 0.04
9q34.1 ABL1 0.99 0.10 0.84 0.05
10q26 FGFR2 0.98 0.01 0.85 0.06
11p15.5 HRAS 0.79 0.04 0.89 0.06
11q13 CCND1 1.01 0.03 0.98 0.02
11q13 FGF4/FGF3 0.96 0.04 N.D N.D
11q13 EMS1 1.00 0.02 1.11 0.02
11q13.5-q14 GARP 1.08 0.03 1.20 0.16
11q13.5-q14 PAK1 1.11 0.04 1.08 0.10
11q23 MLL 1.09 0.05 N.D N.D
12q23 CCND2 1.10 0.07 0.95 0.04
12p12.1 KRAS2 0.89 0.05 0.97 0.05
12q-q13 WNT1 0.84 0.07 0.86 0.04
12q13.2-q13.3 GLI 0.94 0.04 0.94 0.09
12q13.3 SAS/CDK4 0.92 0.06 0.87 0.06
12q14.3-q15 MDM2 0.93 0.10 0.96 0.07
14q32.3 AKT1 0.89 0.05 1.04 0.03
15q25-q26 IGFR1 1.11 0.02 0.98 0.04
15q26.1 FES 1.07 0.04 0.95 0.02
16p13.1 MRP1 1.03 0.05 0.75 0.03
17q21-q22 TOP2A 0.89 0.03 0.90 0.01
17q21.2 ERBB2 0.95 0.08 0.88 0.05
17q23 RPS6KB1 0.95 0.05 N.D N.D
17q23 D17S1670 0.91 0.04 N.D N.D
18p11.3 YES1 0.97 0.06 0.79 0.04
18q21.3 BCL23¢ 0.92 0.02 0.97 0.06
18q21.3 BCL25¢ 0.92 0.08 0.93 0.07
19p13.2 INSR 0.99 0.00 1.12 0.01
19p13.2 JUNB 1.03 0.02 0.82 0.07
19q13.1 CCNE1 0.87 0.03 0.85 0.10
20q12 AIB1 1.44 0.03 1.29 0.01
20q13 STK15 1.28 0.07 1.39 0.18
20q13 CSE1L 1.30 0.04 N.D N.D
20q13.1 MYBL2 1.18 0.03 0.86 0.02
20q13.1-q13.2 PTPN1 1.32 0.06 1.34 0.06
20q13.2 ZNF217 1.22 0.06 0.95 0.07
21q22.3 CBFA2 1.17 0.07 N.D N.D
22q11.21 BCR 1.01 0.05 N.D N.D
22q12.3-q13.1 PDGFB 1.24 0.05 1.66 0.32
Xq11-q12 AR 5¢ 1.12 0.10 1.40 0.07
Xq11-q12 AR 3¢ 1.15 0.13 N.D N.D
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chromosomes containing regions of chromosome 8. The
SKY results are consistent with the two chromosomes
with only chromosome 8 material and also the chromo-
some 8 translocation detected by FISH. The chromo-
some count of both the Davidson et al. [18] study and
the MDA-MB-435-PMCC give a modal number of 57.
This is also the average modal number for all studies of
Table 2. PCR-RFLP genotype analysis of P450 (CYP) and MDR-1.
CYP2C8*2 CYP2C8*3 CYP2C9*2 CYP2C9*3 CYP2C19*2 CYP2C19*3 CYP2D6*4 CYP2D6*4 PGP/MDR1
MDA-MB-435-LCC wt/wt wt/wt wt/wt wt/wt wt/wt wt/wt *4/*4 wt/wt VR/VR
MDA-MB-435-DTP wt/wt wt/wt wt/wt wt/wt wt/wt wt/wt *4/*4 wt/wt VR/VR
MDA-MB-435/LCC-6 wt/wt wt/wt wt/wt wt/wt wt/wt wt/wt *4/*4 wt/wt VR /VR
Figure 1. Cytochrome P450 2D6 genotyping of MDA-MB-435-LCC
and MDA-MB-435-LCC-DTP. Genomic DNA was isolated from the
cancer cell lines and used as template for PCR-RFLP genotyping. PCR
products were digested and separated on a 2% agarose gel. The wild-
type allele for CYP2D6 produces two bands, 190-bp and 163-bp in
length while the CYP2D6*4 allele remains undigested (353-bp band).
Table 3. Results of short tandem repeat (STR) PCR analysis.
DNA STR Locus MDA-MB-435-LCC MDA-MB-435-DTP
D8S1179 13 13
D21S11 30 30
D18S51 13, 17 13, 17
D3S1358 14 14
VWA 16, (18)* 16, (18)*
FGA 21 21
D5S818 11, 12 (11)*, 12
D13S317 12 12
D7S820 8 8, (10)*
THO1 6, 7 6, 7
TPOX 8, (11)* (8)*, 11
CSF1PO 11 11
D16S539 13 13
Amelogenin X X
( )*, peak height differences of £ 60%.
Figure 2. Microsatellite fingerprint comparison of MDA-MB-435-
LCC and MDA-MB-435-PMCC. Microsatellite markers (indicted on
the left of the figure) were PCR amplified and the alleles separated on a
denaturing polyacrylamide gel. The fluorescently labelled DNA
products were detected using a scanning fluorescence imager (Bio-Rad,
FX Molecular Imager). Identical alleles were detected for all markers
except that MDA-MB-435-LCC showed loss of heterozygosity for the
chromosome 8q markers D8S300 and D8S326.
Table 4. Microsatellite analysis of chromosome 8p showing sizes of
alleles in bp.
MDA-MB-435-PMCC MDA-MB-435-LCC
D8s550 256, 270 270
D8s532 244, 246 244
D8s1820 103, 109 109
D8s136 69, 73 69
D8s1706 272, 274 272
D8s255 116, 126 116
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the MDA-MB-435 cell line (Table 5). The CGH profile
obtained in the Davidson et al. [18] study most closely
resembles the MDA-MB-435-PMCC profile as it shows
gain of 7q and no gain of 8q or loss of 18p. These
results suggest that the MDA-MB-435-PMCC cell line
more closely resembles the MDA-MB-435 cell line stud-
ied worldwide, and that the MDA-MB-435-LCC is a
variant cell line that has evolved over time to have
minor changes. The karyotype of various versions of
the MDA-MB-435 cell line are given in Table 5.
Gene expression profiling further supported the close
relationship of MDA-MB-435-LCC and MDA-MB-
435-PMCC cells (Figure 4). Each of these cell lines, and
replicates thereof, were clustered together but distinctly
from other human breast cancer cell lines arrayed
(MDA-MB-468, MDA-MB-453, PMC42-LA ± EGF,
NCI/ADR-RES, T47D, and SK-Br-3 cells ± EGF) as
part of a larger study. As expected, duplicates of the
MDA-MB-435 cell lines clustered together, as did the
EGF-treated and -untreated PMC42-LA and SK-Br-3
cell lines. While this is an unsupervised visualisation of
the data, the outcome is consistent with that reported
by Ross et al. [6] in that MDA-MB-435 and its variants
do not cluster with other breast cancer cell lines. Three
specific subclusters were identified to illustrate the dif-
ferential gene expression between the MDA-MB-435-
LCC and MDA-MB-435-PMCC: the ‘top cluster’ is
more abundant in MDA-MB-435-PMCC, while the
‘middle’ and ‘bottom’ clusters are more abundant in
MDA-MB-435-LCC, consistent with our recent deter-
mination of the identity of MDA-MB-435-LCC15 cells
as MDA-MB-435-LCC; these cell lines show very high
levels of similarity. The gene identity of the elements in
each of these clusters is shown in Table 6.
Having shown that the MDA-MB-435-LCC and
MDA-MB-435-DTP originated from the same cell line
but were not identical, we wished to confirm the
expression of the melanocycte-specific tyrosinase gene.
Tyrosinase expression was seen for all of the MDA-
MB-435 sublines tested including the MDA-MB-435-
LCC, MDA-MB-435/LCC6, MDA-MB-435-DTP, and
the MDA-MB-435S subline obtained from the ATCC
(data not shown), while MCF-7 and MDA-MB-231
cell lines were negative.
Discussion
We have shown that the MDA-MB-435-DTP cells
used in the NCI60 cell screen were representative of
those commonly used in the breast cancer research
community. Our studies showed minor differences in
both genetic variation and gene expression criteria
between MDA-MB-435 cells obtained at different
time points from the MD Anderson Cancer Center
and maintained in an Australian research centre
(MDA-MB-435-PMCC), maintained for a number of
years at the Lombardi Cancer Center in Washington,
DC, USA, and also transferred to the Thompson lab-
oratory in Australia in 1997 (MDA-MB-435-LCC), or
obtained from the NCI study (MDA-MB-435-DTP).
We have also shown that the MDA-MB-435-PMCC
cell line is very similar to the version of the cell line
reported by Davidson et al. [18]. The CGH analysis
in both these studies and the comparison of the FISH
and SKY results for chromosome 8 support a com-
mon origin. Examination of the published karyotypes
of the MDA-MB-435 cell line over time (Table 5)
Figure 3. FISH analysis of MDA-MB-435-LCC and MDA-MB-435-LCC-PMCC. Each cell line was examined by FISH for chromosome 8. (a)
Positions of the 10 chromosome 8 probes analysed by FISH. (b) Distribution of the chromosome 8 material in the two MDA MB 435 cell lines.
548 J.M. Rae et al.
shows common marker chromosomes, suggesting that
the current cell lines have evolved from those origi-
nally reported. These data address an important con-
cern as to whether the MDA-MB-435-DTP cells,
which were first shown to exhibit melanoma-specific
gene expression, were truly representative of those
used in other laboratories. Our data show commonal-
ity with representative stocks in North America, Aus-
tralia and Europe. Also, the widespread and growing
confirmation of melanoma-specific traits [7–10, 19]
supports our observation that the MDA-MB-435-
DTP cells are truly representative.
Table 5. Karyotype analysis of MDA-MB-435 cell lines.
Chr. MDA-MB-435
Satya-Prakash
et al. [28] by
karyotyping
14 markers
(5 unidentified)
MDA-MB-435
Price et al. [29]
by karyotyping
13 markers
(1 unidentified)
MDA-MB-435
Leonessa et al. [11]
by karyotyping
18 markers
(3 unidentified)
MDA-MB-435
Davidson et al [18]
by SKY
21 markers
(All identified)
MDA-MB-435S
(www.atcc.org),
by karyotyping
19 markers
(all unidentified)
1 1 · 3 1 · 2
t (1q;7q),del(1q)qter)
1 · 1
t(1q;7q), t(1p;?)
1 · 1,
der(1)t(1;7), der(1)t(1;10)
1 · 2
2 2 · 3 2 · 3 2 · 2 2 · 2,
del(2)(p?)
2 · 3
3 3 · 3 (3p)) 3 · 2
del(3p > pter),
t(3p:?)
3 · 2 del(3)(q21:)*,
del(3)(p21p24)*
3 · 2,
del(3)(p?),
der(3)t(3;19)
3 · 2, marker
4 4 · 2 4 · 2 4 · 2 4 · 2 4 · 2
5 5 · 2 (5p;13q) 5 · 3 5 · 3 5 · 2,
del(5)(q?)
5 · 2
6 6 · 3 (6q)) 6 · 1
t(6q;?), del (6q > qter)
6 · 2 del
(6)(q12q21)*
6 · 2,
der(6)t(6;7)
6 · 0,
three markers
7 7 · 3 (7p)) 7 · 2 7 · 2 7 · 2 7 · 1,
six markers
8 8 · 2 (8q+) 8 · 2 t(8q;?) 8 · 1 (8q + )*,
del(8)(p11p21)
8 · 1,
del(8)(p),
der(8)t(8;15)
8 · 2
9 9 · 3 9 · 3 9 · 2 t(9q;?) 9 · 2 9 · 2
10 10 · 2 10 · 2 10 · 2 10 · 2, del(10),
der(10)t(10;18)
10 · 2
11 11 · 1
t(14q:11q) · 2
11 · 1
t(11p:?)
11 · 1
t(11q;14q)*
11 · 2, der(11)t(8;11) 11 · 0
12 12 · 2 12 · 2 12 · 2 12 · 2 12 · 2
13 13 · 1 t(?:13) 13 · 1
t(11q:13q)
13 · 1
t(11q;13q)
13 · 1, der(13)
t(11;13)
13 · 1
14 14 · 2 14 · 2 (1 may
be a marker)
14 · 1
(14p + (HSR))
14 · 1,
der(14)t(1;14),
der(?)t(14;16)
14 · 2
15 15 · 2 15 · 2 15 · 2 15 · 2 15 · 2, marker
16 16 · 2 16 · 2
t(11p:16q)
16 · 2 16 · 2 16 · 2
17 17 · 3 17 · 4 (1 may
be a marker)
17 · 2 17 · 2 17 · 2, marker
18 18 · 2 18 · 2 (1 may
be a marker)
18 · 2
del(18)(q12q22)
18 · 1,
der(?)t(18;19)
18 · 1
19 19 · 2 19 · 2 (1 may
be a marker)
19 · 1 19 · 1,
der(?)t(6;19)
19 · 1
20 20 · 0
(20p+) · 2
20 · 0 t(20q;?) 20 · 0
(20q + )*
20 · 1, del(20),
der(?)t(20;21) · 2
20 · 2, marker
21 21 · 1 21 · 2 21 · 1 21 · 1 21 · 1
22 22 · 1 22 · 2
t(22p;?) · 2
22 · 1 (22p + )*,
(22p+) t(11p;22q)
22 · 2,
der(22?)t(6;22)
22 · 0
X X · 2 X · 2 X · 2 or 1 X · 2 X · 2
modal Chr # (range) 64 (59–67) 55–56 not done? 57 (44–62) 56 (55–62)
These marker chromosomes in MDA-MB-435 cell line described by Leonessa et al. [11] are identical to markers seen in Satya-Prakash et al. [28].
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Some variation in chromosome 8 was seen between
the MDA-MB-435-PMCC and MDA-MB-435-LCC
cells, with consistent changes seen by microsatellite
analysis (low and high density) and high density FISH.
Reproducible differences were also seen at the gene
expression profile level, however, there were not local-
ised to chromosome 8 and either represent additional
genomic changes as detected by CGH, or indirect
effects of these genomic changes on the transcriptome.
The most likely explanation for this variation is that
the MDA-MB-435-LCC cell line has undergone a
passage-related loss of heterozygosity (LOH) for part
or all of chromosome 8, and/or preferential expansion
of this subpopulation from clonal heterogeneity at
some point, although to our knowledge the cell lines
used here were never purposefully cloned. The changes
described above are reminiscent of the plethora of
studies on phenotypic drift reported in a rat mammary
adenocarcinoma system in the early 1980s [20–23], as
also notably reported with different versions of the
human mammary MCF7 [24] and T47D [4] cells lines
where tremendous drift has been encountered, leading
to many variants in different hands with different ER/
PR status.
The MDA-MB-435 cell line has been the subject of
considerable debate, since Ross et al. [6] showed that
they clustered with human melanoma cell lines in a
large scale expression profile analysis of 60 human cell
Figure 4. Microarray gene expression profiling of selected breast cancer cell lines. Two dimensional hierarchial clustering was applied to an
expression dataset obtained from 5000 element (cDNA) Research Genetics ‘breast arrays’. Shown at (a) is the derived cell-line dendrogram
depicting similarity of lines based on a total of 3800 genes. Of note is that the MDA-MB-435 replicate collection and array interrogations for any
individual line show greatest homology. At (b) is a subset of 453 genes which highlight the similarities and differences between MDA-MB-435
isolates. This is broken out into threee separate subsets at (c). The names of each element within the clusters at (c) are shown in Table 6.
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lines from 12 different organs of origin. Further evi-
dence supporting the melanocytic origin of MDA-MB-
435 cells is provided by Lee et al. [8] who showed that
MDA-MB-435 xenografts expressed several genes
involved in melanin biosynthesis and pigmentation
including melan-A, ocular albinism 1 and tyrosinase-
related protein 1. Jessani et al. [7] showed that the ser-
ine protease activity profile of MDA-MB-435 cells
resembled melanoma cell lines rather than breast can-
cer cell lines, and MDA-MB-435 cells were shown by
2D gel electrophoresis profiling to resemble melanoma
cell lines in their secretesome [10]. Ellison et al. [9]
showed that MDA-MB-435 cells transfected with
hepatocyte growth factor expressed several melano-
cyte-specific genes including ACP-5, tyrosinase-related
protein and the melanocyte-specific gene tryrosinase.
We confirmed here that MDA-MB-435-LCC, the asci-
tes-derived MDA-MB-435/LCC6, MDA-MB-435-DTP
and MDA-MB-435S cells expressed tyrosinase. It is
interesting to note that Ellison et al. [9] did not find
tyrosinase expression in the MDA-MB-435S cells
which they obtained from the ECACC, and also found
reduced levels of RXR and tyrosinase-related protein,
again suggesting some drift among different holdings
of the same cell line. In supplementary material (http://
genome-www.stanford.edu/nci60/supplement.shtml) Ross
et al. [6] indicated that MDA-MB-435S showed only
part of the melanoma signature seen with MDA-MB-
435-DTP, and using RFLP analysis confirmed that
they were clonally related, to an extent seen in first
degree relatives.
In the Ross study [6], MDA-MB-435-DTP and
their erbB2-transfected variant MDA-N clustered next
to each other and within the group containing seven
melanoma cell lines, co-expressing approximately 90
melanoma-specific gene products. Although this is a
strong evidence supporting a melanocytic origin of
MDA-MB-435 cells, it has been questioned due to the
fact that not all of the breast cancer cell lines clustered
into a distinct group. The three MCF-7 samples and
the T-47D cells did cluster together, consistent with
their oestrogen receptor-positive status and their
requirement for oestrogen to grow, while the Hs578T
and BT-549 cells clustered with CNS tumours and the
MDA-MB-231 cells did not appear to cluster with any
group. The Hs578T, BT-549 and MDA-MB-231 cell
lines each show attributes consistent with epithelial to
mesenchymal transition (EMT) [25], a phenotypic con-
version deployed during development when epithelial
cells need to move to another site, and a process that
is gaining acceptance as a mechanism for carcinoma
metastasis [26]. Another dramatic transdifferentiation
similar to that seen with EMT is vasculogenic mimicry
[27]. It is possible to speculate that the lack of cluster-
ing of the Hs578T, BT-549 and MDA-MB-231 cell
lines represents such transitions, and a similar pheno-
typic transdifferentiation program may have occurred
in the MDA-MB-435 cells, resulting in expression of a
host of melanoma-specific genes. Recently, Sellappan
et al. [19] showed expression of both melanoma-spe-
cific and epithelial-specific gene products in MDA-
MB-435 cells, suggesting that lineage-infidelity may
have occurred, and citing examples where this has been
seen clinically.
Our own microarray analysis shows that the MDA-
MB-435 cells cluster away from a variety of human
breast cancer cell lines, and additional microarray
studies of MDA-MB-435-LCC cells at the Lombardi
Cancer Center show these cells to be less similar to
breast cancer biopsies from patients than other widely
used breast cancer cell lines (Clarke, manuscript in
preparation). In total, these data imply that MDA-
MB-435 cells are not representative of breast cancer,
however, one cannot rule out the possibility that they
represent the end result of a specific transdifferentia-
tion such as seen with EMT or acquired through line-
age infidelity. They retain certain mammary features,
as detailed by Sellappan et al. [19], and although these
Table 6. Gene identifiers for cluster groups shown in Figure 4. Cluster ordered groups are presented here as depicted in Figure 4c. The IDs
are based on Research Genetics Unigene Build 146 for ‘breast specific’ GF225 arrays.
Top cluster (more abundant in MDA-MB-435-PMCC)
MGC4276, HSPA9B, ATP1B2, TTF-I interacting peptide, THBS4, FXR2, ESTs, ACTA2, USP21, PMS2L5, C1D, DKFZp434P228,
SCAMP2, CCR1, KIAA0215, CD68
ESTs, TNRC3, DKFZp434P0531, DKFZp761G2113, PCTK1, MINK, CLDN7, BPHL, KIAA1292, CALM3, MECP2, ESTs, FLJ20417,
ESTs, CLASP1, LOC51064, PDGFRL, TNFRSF5, ESTs, ESTs, SHC1, APOD, COP9, FLJ20457, HTATSF1, KIAA0515, UXT
CYC1, ESTs, PEA15, DRPLA, CNOT7, EIF2S2, P311, ESTs, CELSR2, ESTs, PHLDA3, ESTs, FLJ23138, KIAA0016, CENPB
Middle cluster (more abundant in MDA-MB-435-LCC)
IFRD2, ESTs, IAA110, FLB5227 PRO1367, ESTs, KPNA1, DKFZP564O123, CYP27A1, CENPA, MYO10, MAGEA3, NOT56L,
DSCR1, CFDP1, FLJ22704, KIAA0610, ACAA2, UP, ALDH1A1, MXI1, MAIL, CD44, SAT, SAT, SAT, PEPD,
HSPA4, FYN, SPRY2, procollagen-lysine, HMOX2, cDNA DKFZp434E082, KIAA0155, EIF1A, KIAA0678, SOD1, CGI-203, ubiqui-
tin-protein ligase, MAPRE2, FLJ21778 fis, NLVCF
Lower cluster (more abundant in MDA-MB-435-LCC)
ERO1L, MGC4825, NBL1, SLC25A4, NFIC, MDS019, SAP30, C6orf5, RPL24, ESTs, SLC25A4, ESTs, FLJ14934 fis, AD036, GNG2,
DREV1, RAP1, DDX24, MGC14156, KIAA0332, FLJ11342, NEDD5, SFRS4, MRPL34, HSP105B, ATOX1, ESTs, KIAA0326, GYG,
LDHA, LDHA,SOD1, ESTs, UFD1L, PTP4A1, ITPKB, FLJ21007, MRPL3, CUGBP2, FLJ14753, RAB7
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may continue to influence metastasis in a breast can-
cer-specific way, we feel that their limited resemblance
to other breast cancers (including breast cancer cell
lines and primary breast cancers) warrants caution in
their use as a definitive breast cancer model.
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